Prince of Wales Clinical School, UNSW Sydney, NSW 2031, Australia.
School of Medical Sciences, UNSW Sydney, NSW 2052, Australia.
Clin Neurophysiol. 2018 May;129(5):889-894. doi: 10.1016/j.clinph.2018.02.120. Epub 2018 Mar 6.
To demonstrate construct validity of the Total Neuropathy Score (TNS) in assessing peripheral neuropathy in subjects with chronic kidney disease (CKD).
113 subjects with CKD and 40 matched controls were assessed for peripheral neuropathy using the TNS. An exploratory factor analysis was conducted and internal consistency of the scale was evaluated using Cronbach's alpha. Construct validity of the TNS was tested by comparing scores between case and control groups.
Factor analysis revealed valid item correlations and internal consistency of the TNS was good with a Cronbach's alpha of 0.897. Subjects with CKD scored significantly higher on the TNS (CKD: median, 6, interquartile range, 1-13; controls: median, 0, interquartile range, 0-1; p < 0.001). Subgroup analysis revealed construct validity was maintained for subjects with stages 3-5 CKD with and without diabetes.
The TNS is a valid measure of peripheral neuropathy in patients with CKD.
The TNS is the first neuropathy scale to be formally validated in patients with CKD.
证明总神经病变评分（TNS）在评估慢性肾脏病（CKD）患者周围神经病变方面的结构效度。
使用 TNS 对 113 例 CKD 患者和 40 例匹配的对照者进行周围神经病变评估。进行了探索性因子分析，并使用 Cronbach's alpha 评估量表的内部一致性。通过比较病例组和对照组的评分来检验 TNS 的结构效度。
因子分析显示项目间具有有效的相关性，TNS 的内部一致性良好，Cronbach's alpha 为 0.897。CKD 患者的 TNS 评分明显更高（CKD：中位数 6，四分位距 1-13；对照组：中位数 0，四分位距 0-1；p<0.001）。亚组分析显示，有和无糖尿病的 3-5 期 CKD 患者的 TNS 均具有结构效度。
TNS 是 CKD 患者周围神经病变的有效测量工具。
TNS 是第一个在 CKD 患者中得到正式验证的神经病变量表。
